X

Xenon Pharmaceuticals

Clinical-stage neurological disorder therapeutics developer

Executive Director, Total Rewards

Full-Time
$241.1k - $304.9k/yr
Expert
Bachelor's, MBA
Boston, MA, USA+2 moreMore locations: Needham, MA, USA | Vancouver, BC, Canada
HybridHybrid positions require a minimum of two onsite days per week.
People & HRCompensation & Benefits

About the job

Requirements
  • A relevant undergraduate degree, including coursework in mathematics, accounting, finance, and/or law.
  • At least 15 years of experience in progressive compensation or human resources management roles in public, multinational life sciences organizations experiencing rapid growth and change.
  • Deep business acumen and understanding of how business strategy in biopharma affects total rewards.
  • Deep hands-on experience and expertise in data and systems, with very strong attention to detail.
  • Strong analytical and conceptual capability, problem-solving, and business planning skills, and the ability to develop and successfully execute strategies at an organizational level.
  • Ability to adapt and quickly pivot according to business needs.
  • Excellent written and oral communication skills, including compensation context and employee messaging for executive and non-executive audiences.
  • Ability to collaborate effectively and build relationships with key stakeholders.
  • Ability to execute multiple high-priority projects using organizational, prioritization, and project management skills.
  • Strong skills in Office software, HR and Finance systems, and data.
Responsibilities
  • Lead the design, implementation, and governance of competitive, integrated total rewards strategies—including base salary, bonus, equity, recognition, and benefits—in collaboration with the EVP of HR and external advisors, to attract talent, reward performance, and support retention in Canada and the United States.
  • Lead and manage the base salary program, including budget and forecast, workforce planning, annual review, job design and matching, salary ranges, pay transparency, legal compliance, annual and promotion increase guidance, and metrics and analysis; coach HR business partners; and coordinate with HR Operations and Finance/Payroll to ensure accurate and timely compensation and promotion activities.
  • Lead and manage incentive compensation for non-Sales employees; collaborate with Sales Management and the Commercial HR business partner on Sales employee program design; align plans with performance expectations and coordinate with the performance management program lead.
  • Coordinate the design, evolution, and management of equity programs, including stock options, full value share plans, and potentially deferred compensation programs, in collaboration with executive leaders and the Compensation Committee.
  • Support the EVP of HR in managing external compensation consultants and preparing materials for the Compensation Committee and Board of Directors.
  • Review and provide input on compensation governance reports, including proxy Compensation Discussion and Analysis, collaborating with Finance and Legal as required.
  • Lead and manage non-financial employee recognition programs with HR business partners and HR Operations.
  • Lead and manage United States benefits, including health-related benefits and 401(k), from design proposals and benchmarking through contracting, employee communications, and governance.
  • Oversee compensation details for accurate forecasting in the Annual Operating Plan and five-year Plan financial data.
  • Collaborate with HR business partners on the evolution of the Career Framework, particularly its compensation philosophy and programs.
  • Collaborate with the HR systems and data team to review and recommend systems that streamline compensation and other reward programs in alignment with the Company and HR systems roadmap.
  • Manage participation in compensation surveys in Canada and the United States.
  • Collaborate with HR business partners, Finance, and other functions to create communication strategies that foster employee and candidate understanding of total rewards programs.
  • Build relationships with leaders and internal partners to inform total rewards programs aligned with business objectives.
  • Maintain current knowledge of life sciences compensation trends and governance, and drive thought leadership on emerging trends and challenges.
  • Champion the Company's evolving culture and values.
  • Develop short- and long-term objectives for the function in accordance with Company strategies and plans.
  • Plan and manage budget proposals and approved budgets in accordance with Company plans and Finance policies.
  • Recruit, lead, direct, develop, coach, and evaluate direct reports, if any, in accordance with Human Resource policies and practices.
  • Ensure Company policies, including the Code of Business Conduct and Ethics, are understood and followed by direct reports, if any.
  • Some international travel may be required.
  • Perform other duties as assigned.
Desired Qualifications
  • An MBA is strongly preferred.
  • Experience in both pre-commercial and commercial companies is strongly preferred.
  • Experience preparing materials for and interacting with the Board and/or Compensation Committee is ideal.

About the company

Xenon develops therapies for neurological disorders, especially epilepsy, in a clinical-stage biopharma setting, using research, partnerships, and licensing to move candidates toward commercialization. Its products are designed to act on neurological and genetic targets, with XEN007 in Phase 2 for treatment-resistant pediatric absence epilepsy illustrating its development pathway and reliance on clinical testing. The company differentiates itself by focusing on genetics-informed neurology and a pediatric, targeted epilepsy pipeline supported by collaborations rather than broad, one-size-fits-all approaches. The goal is to discover, develop, and eventually bring to patients therapies that address unmet neurological needs, advancing outcomes through a strong clinical pipeline and strategic partnerships.

Company Size

201-500

Company Stage

IPO

Headquarters

Burnaby, Canada

Founded

1996

Get referred to Xenon Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • X-TOLE2 and X-TOLE3 keep enrolling, preserving epilepsy approval momentum.
  • X-NOVA2 remains powered at 360 patients, with topline due Q1 2027.
  • Executives bought $1.68 million shares on September 18, 2026, signaling confidence.

What critics are saying

  • September 17 pause in MDD and bipolar trials exposes azetukalner neuropsychiatric toxicity.
  • Psychosis, aphasia, and ataxia can shrink psychiatry upside and trigger FDA labeling.
  • If FDA rejects azetukalner or requires studies, Xenon's single-asset thesis breaks.

What makes Xenon Pharmaceuticals unique

  • Azetukalner is a first-in-class KV7 opener spanning epilepsy and psychiatry.
  • September 17, 2026 NDA submission gives Xenon its first commercialization path.
  • $1.25 billion cash funds operations into 2029, reducing near-term dilution.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Short-& Long-term Disability

Accidental Death & Dismemberment

Life Insurance

Employee Assistance Program

401(k) Company Match

Stock Options

Tuition Reimbursement

Paid Vacation

Paid Sick Leave

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Oct 1st, 2026
Xenon executives buy $1.68M in shares as epilepsy drug heads to FDA

Xenon Pharmaceuticals saw its top executives purchase $1.68 million in shares on Thursday. CEO Ian Mortimer bought 30,000 shares worth approximately $1.12 million, whilst CFO Thomas Kelly acquired 15,000 shares for nearly $560,000. The biotech company submitted its lead drug Azetukalner to the FDA last month for focal onset seizures treatment, following positive Phase 2b and Phase 3 trial results. Xenon temporarily paused new patient enrollment in psychiatry studies after observing neuropsychiatric side effects, though this doesn't affect its epilepsy programme. The clinical-stage company ended Q2 with approximately $1.25 billion in cash and investments, which management expects will fund operations into 2029.

GlobeNewswire
Sep 21st, 2026
Xenon to present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit.

Xenon to present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit. VANCOUVER, BC and BOSTON, MA, Sept. 21, 2026 (GLOBE NEWSWIRE) - Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, today announced that the company will present at an upcoming investor conference: * TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, Virtual Fireside Chat: Wednesday, September 23, 2:00-2:25 pm ET Details about the presentation, including webcast information, can be found on the Investors section of Xenon's website. When available, webcasts are posted for replay following the event. The above-listed dates and times are subject to change. About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon's lead molecule, azetukalner, is a novel, potent K[V] 7 potassium channel opener in late-stage clinical development for the treatment of epilepsy, major depressive disorder and bipolar depression. Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including K[V] 7 and Na[V] 1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X. Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada and elsewhere. All other trademarks belong to their respective owner. For Media: Colleen Alabiso Senior Vice President, Corporate Affairs [email protected]

Yahoo Finance
Sep 20th, 2026
Xenon Pharmaceuticals shares drop 32% after pausing psychiatry trials despite positive epilepsy NDA filing

Xenon Pharmaceuticals' shares fell 32.2% after the company voluntarily paused new enrolment in its Phase 3 major depressive disorder and bipolar depression studies due to neuropsychiatric adverse events. The decision came on the same day Xenon submitted a New Drug Application to the US FDA for azetukalner in focal seizures. The NDA is supported by two randomised, double-blind, placebo-controlled trials showing statistically significant seizure reduction and a consistent safety profile across more than 1,500 patient-years of exposure. The pause in psychiatry trials does not directly affect the epilepsy NDA or ongoing Phase 3 seizure studies, which remain the main driver of the company's investment narrative.

Seeking Alpha
Sep 18th, 2026
Xenon downgraded at Deutsche Bank after pause in depression trials.

Xenon downgraded at Deutsche Bank after pause in depression trials. Xenon Pharmaceuticals (XENE) fell 30% to reach its lowest level since November after the company paused enrollment in Phase 3 depression trials for its lead asset, azetukalner, following safety concerns, leading to a downgrade at Deutsche Bank. Analyst David Hoang Fresh Stock Ideas, Every Day Explore diverse investing perspectives with daily analysis from experts across the market.

TradingView
Sep 18th, 2026
Xenon downgraded at Deutsche Bank after pause in depression trials.

Xenon downgraded at Deutsche Bank after pause in depression trials. Xenon Pharmaceuticals XENE fell 30% to reach its lowest level since November after the company paused enrollment in Phase 3 depression trials for its lead asset, azetukalner, following safety concerns, leading to a downgrade at Deutsche Bank. Analyst David Hoang downgraded the Canadian biotech to Hold from Buy after the company paused enrollments in multiple late-stage trials for azetukalner in major depressive disorder and bipolar depression in reaction to several neuropsychiatric adverse events, including psychosis. However, Xenon XENE management argued that the decision was a temporary measure taken as a precaution and there won't be an impact on ongoing epilepsy studies.The nature of the events, as well as their severity and frequency, were in line with the known safety and tolerability profile of the drug, the company added. Despite those remarks, Hoang said, "We disagree and believe this impairs the molecule's overall profile as a potential best-in-class drug that would become the go-to, branded antiseizure medication of choice in focal epilepsy." The analyst slashed his price target on XENE to $46 from $90 per share. However, Stifel, Baird, and RBC Capital Markets were among the firms to reaffirm their bullish ratings on the stock. While the surprising decision leads to uncertainty, "we're confident there's minimal readthrough to FOS," Stifel analyst Paul Matteis wrote with a Buy rating, according to Bloomberg. RBC Capital Markets analyst Brian Abrahams reiterated his Outperform rating yet trimmed his price target to $70 from $81, noting, "We believe the core value remains epilepsy and do not see any major risk to the filing timelines or commercial launch." Baird analyst Brian Skorney also sounded cautious, lowering his price target to $90 from $97 despite an outperforming rating. "We still think the MDD study is adequately powered into the 1Q topline, and we see low-rate psychosis as an AE neurologists are equipped to manage," Skorney added.Disclaimer Content provided by Seeking Alpha is intended for information purposes only, and that Seeking Alpha does not offer any personalist investment advice and is not a licensed securities dealer, broker, US investment adviser or investment bank.